Amorphous solid dispersions: Rational selection of a manufacturing process

Teófilo Vasconcelos; Sara Marques; José das Neves; Bruno Sarmento

doi:10.1016/j.addr.2016.01.012

journal article May 01, 2016

Amorphous solid dispersions: Rational selection of a manufacturing process

Teófilo Vasconcelos Sara Marques José das Neves Bruno Sarmento

Advanced Drug Delivery Reviews Vol. 100 pp. 85-101 · Elsevier BV

View at Publisher Save 10.1016/j.addr.2016.01.012

Topics

No keywords indexed for this article. Browse by subject →

References

196

[1]

Ku "Use of the biopharmaceutical classification system in early drug development" AAPS J. (2008) 10.1208/s12248-008-9020-0

[2]

Benet "BDDCS applied to over 900 drugs" AAPS J. (2011) 10.1208/s12248-011-9290-9

[3]

The future of molecular dynamics simulations in drug discovery

David W. Borhani, David E. Shaw

Journal of Computer-Aided Molecular Design 2012 10.1007/s10822-011-9517-y

[4]

Marshall "Computer-aided drug design" Annu. Rev. Pharmacol. Toxicol. (1987) 10.1146/annurev.pa.27.040187.001205

[5]

Kawakami "Current status of amorphous formulation and other special dosage forms as formulations for early clinical phases" J. Pharm. Sci. (2009) 10.1002/jps.21816

[6]

Vasconcelos "Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs" Drug Discov. Today (2007) 10.1016/j.drudis.2007.09.005

[7]

Leuner "Improving drug solubility for oral delivery using solid dispersions" Eur. J. Pharm. Biopharm. (2000) 10.1016/s0939-6411(00)00076-x

[8]

Ku "A biopharmaceutical classification-based right-first-time formulation approach to reduce human pharmacokinetic variability and project cycle time from first-In-human to clinical proof-of-concept" Pharm. Dev. Technol. (2012) 10.3109/10837450.2010.535826

[9]

Streubel "Drug delivery to the upper small intestine window using gastroretentive technologies" Curr. Opin. Pharmacol. (2006) 10.1016/j.coph.2006.04.007

[10]

Membrane transporters in drug development

Kathleen M. Giacomini, Shiew-Mei Huang, Donald J. Tweedie et al.

Nature Reviews Drug Discovery 2010 10.1038/nrd3028

[11]

Cutler "Development of a P-glycoprotein knockout model in rodents to define species differences in its functional effect at the blood–brain barrier" J. Pharm. Sci. (2006) 10.1002/jps.20658

[12]

Seo "Improved oral absorption of cilostazol via sulfonate salt formation with mesylate and besylate" Drug Des. Devel. Ther. (2015)

[13]

Novozhilov "An improved kilogram-scale preparation of atorvastatin calcium" Chem. Cent. J. (2015) 10.1186/s13065-015-0082-7

[14]

Sarkar "Molecular salts and co-crystals of mirtazapine with promising physicochemical properties" J. Pharm. Biomed. Anal. (2015) 10.1016/j.jpba.2015.03.003

[15]

Serrano "Emerging nanonisation technologies: tailoring crystalline versus amorphous nanomaterials" Curr. Top. Med. Chem. (2015) 10.2174/1568026615666150605122917

[16]

Zhang "From a binary salt to salt co-crystals of antibacterial agent lomefloxacin with improved solubility and bioavailability" Acta Crystallogr. Sect. B: Struct. Sci. Cryst. Eng. Mater. (2015) 10.1107/s2052520615011191

[17]

Chadha "Characterization and evaluation of multi-component crystals of hydrochlorothiazide" Pharm. Res. (2014) 10.1007/s11095-014-1344-0

[18]

Weuts "Salt formation in solid dispersions consisting of polyacrylic acid as a carrier and three basic model compounds resulting in very high glass transition temperatures and constant dissolution properties upon storage" Eur. J. Pharm. Sci. (2005) 10.1016/j.ejps.2005.04.011

[19]

Seefeldt "Crystallization pathways and kinetics of carbamazepine–nicotinamide cocrystals from the amorphous state by in situ thermomicroscopy, spectroscopy, and calorimetry studies" J. Pharm. Sci. (2007) 10.1002/jps.20945

[20]

Dimopoulou "In-vitro evaluation of performance of solid immediate release dosage forms of weak bases in upper gastrointestinal lumen: experience with miconazole and clopidogrel salts" J. Pharm. Pharmacol. (2015)

[21]

Terebetski "Combined use of crystalline sodium salt and polymeric precipitation inhibitors to improve pharmacokinetic profile of ibuprofen through supersaturation" AAPS PharmSciTech (2014) 10.1208/s12249-014-0163-2

[22]

Sai Gouthami "Can crystal engineering be as beneficial as micronisation and overcome its pitfalls?: A case study with cilostazol" Int. J. Pharm. (2015) 10.1016/j.ijpharm.2015.06.009

[23]

Bhakay "Novel aspects of wet milling for the production of microsuspensions and nanosuspensions of poorly water-soluble drugs" Drug Dev. Ind. Pharm. (2011) 10.3109/03639045.2010.551775

[24]

Pouton "Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system" Eur. J. Pharm. Sci. (2006) 10.1016/j.ejps.2006.04.016

[25]

Prabhu "Novel lipid-based formulations enhancing the in vitro dissolution and permeability characteristics of a poorly water-soluble model drug, piroxicam" Int. J. Pharm. (2005) 10.1016/j.ijpharm.2005.05.032

[26]

Gupta "Formulation strategies to improve the bioavailability of poorly absorbed drugs with special emphasis on self-emulsifying systems" ISRN Pharm. (2013)

[27]

Laitinen "Emerging trends in the stabilization of amorphous drugs" Int. J. Pharm. (2013) 10.1016/j.ijpharm.2012.04.066

[28]

Karolewicz "Solid dispersion in pharmaceutical technology. part II. the methods of analysis of solid dispersions and examples of their application" Polim. Med. (2012)

[29]

Lee "A practical guide to pharmaceutical polymorph screening & selection" Asian J. Pharm. Sci. (2014)

[30]

Murshedkar (2002)

[31]

Tawa (2005)

[32]

Pastrano "Physicochemical characterization of spray dried formulation containing amorphous drug" Int. J. Pharm. Pharm. Sci. (2012)

[33]

Talaczyńska "Application of vibrational spectroscopy supported by theoretical calculations in identification of amorphous and crystalline forms of cefuroxime axetil" Sci. World J. (2015) 10.1155/2015/921049

[34]

Jelińska "The stability of the amorphous form of cefuroxime axetil in solid state" J. Pharm. Biomed. Anal. (2006) 10.1016/j.jpba.2006.02.008

[35]

Urbanetz "Stabilization of solid dispersions of nimodipine and polyethylene glycol 2000" Eur. J. Pharm. Sci. (2006) 10.1016/j.ejps.2005.12.009

[36]

Tanaka "Development of novel sustained-release system, disintegration-controlled matrix tablet (DCMT) with solid dispersion granules of nilvadipine" J. Control. Release (2005) 10.1016/j.jconrel.2005.08.024

[37]

Vilhelmsen "Effect of a melt agglomeration process on agglomerates containing solid dispersions" Int. J. Pharm. (2005) 10.1016/j.ijpharm.2005.07.012

[38]

Karata "Improved solubility and dissolution rate of piroxicam using gelucire 44/14 and labrasol" Farmaco (2005) 10.1016/j.farmac.2005.04.014

[39]

Damian "Physicochemical characterization of solid dispersions of the antiviral agent UC-781 with polyethylene glycol 6000 and gelucire 44/14" Eur. J. Pharm. Sci. (2000) 10.1016/s0928-0987(00)00084-1

[40]

Vasconcelos "Development of An Opicapone Third Generation Solid Dispersion" (2013)

[41]

He "Amorphous solid dispersions: utilization and challenges in drug discovery and development" J. Pharm. Sci. (2015) 10.1002/jps.24541

[42]

Nielsen "Stabilisation of amorphous furosemide increases the oral drug bioavailability in rats" Int. J. Pharm. (2015) 10.1016/j.ijpharm.2015.05.063

[43]

Vo "Current trends and future perspectives of solid dispersions containing poorly water-soluble drugs" Eur. J. Pharm. Biopharm. (2013) 10.1016/j.ejpb.2013.09.007

[44]

Huang "Fundamental aspects of solid dispersion technology for poorly soluble drugs" APSB (2014)

[45]

Lin "Informatic calibration of a materials properties database for predictive assessment of mechanically activated disordering potential for small molecule organic solids" J. Pharm. Sci. (2009) 10.1002/jps.21647

[46]

Sóti "Comparison of spray drying, electroblowing and electrospinning for preparation of eudragit E and itraconazole solid dispersions" Int. J. Pharm. (2015) 10.1016/j.ijpharm.2015.07.076

[47]

Passerini "Melt granulation of pharmaceutical powders: a comparison of high-shear mixer and fluidised bed processes" Int. J. Pharm. (2010) 10.1016/j.ijpharm.2010.03.013

[48]

Homayouni "Preparation and characterization of celecoxib dispersions in Soluplus(®): comparison of spray drying and conventional methods" Iran J. Pharm. Res. (2015)

[49]

Potter "Novel supercritical carbon dioxide impregnation technique for the production of amorphous solid drug dispersions: a comparison to hot melt extrusion" Mol. Pharm. (2015) 10.1021/mp500644h

[50]

Won "Improved physicochemical characteristics of felodipine solid dispersion particles by supercritical anti-solvent precipitation process" Int. J. Pharm. (2005) 10.1016/j.ijpharm.2005.05.017

Showing 50 of 196 references

Metrics

334

Citations

196

References

Details

Published: May 01, 2016
Vol/Issue: 100
Pages: 85-101
License: View

Authors

ICBAS−Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto, Rua Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal; CESPU, IINFACTS−Institute for Research and Advanced Training in Health Sciences and Technologies, Rua Central de Gandra 1317, 4585-116 Gandra, Portugal

Funding

European Regional Development Fund

Fundação para a Ciência e a Tecnologia Award: SFRH/BPD/92934/2013

Cite This Article

Teófilo Vasconcelos, Sara Marques, José das Neves, et al. (2016). Amorphous solid dispersions: Rational selection of a manufacturing process. Advanced Drug Delivery Reviews, 100, 85-101. https://doi.org/10.1016/j.addr.2016.01.012

Amorphous solid dispersions: Rational selection of a manufacturing process

You May Also Like